Is CONSTIPATION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed CONSTIPATION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 115 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported CONSTIPATION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and CONSTIPATION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause CONSTIPATION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes CONSTIPATION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if CONSTIPATION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing CONSTIPATION: 115
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where CONSTIPATION is a reported side effect: 3.4545%

FDA reports of any drug causing CONSTIPATION : 46656
Average percentage for all medicated patients where CONSTIPATION is reported as a complication: 0.2924%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with CONSTIPATION:

FOSAMAX (5673 patients)
ASPIRIN (4491 patients)
VIOXX (3154 patients)
ZOMETA (2855 patients)
CHANTIX (2488 patients)
FORTEO (2430 patients)
LIPITOR (2425 patients)
SEROQUEL (2215 patients)
NEXIUM (2114 patients)
OXYCONTIN (2101 patients)
SYNTHROID (1912 patients)
LASIX (1797 patients)
LISINOPRIL (1776 patients)
NEURONTIN (1742 patients)
PREDNISONE (1740 patients)
ALLI (1709 patients)
LYRICA (1691 patients)
OMEPRAZOLE (1567 patients)
AMBIEN (1547 patients)
XANAX (1509 patients)
DEXAMETHASONE (1482 patients)
COUMADIN (1472 patients)
CYMBALTA (1459 patients)
BYETTA (1450 patients)
PRILOSEC (1441 patients)
ZOLOFT (1424 patients)
AREDIA (1400 patients)
REVLIMID (1393 patients)
PROTONIX (1312 patients)
FUROSEMIDE (1308 patients)
OXYCODONE HCL (1289 patients)
FOLIC ACID (1281 patients)
LORAZEPAM (1274 patients)
PERCOCET (1261 patients)
CELEBREX (1261 patients)
ALBUTEROL (1260 patients)
ATENOLOL (1259 patients)
HYDROCHLOROTHIAZIDE (1249 patients)
VICODIN (1237 patients)
ACETAMINOPHEN (1232 patients)
DURAGESIC-100 (1224 patients)
PREVACID (1206 patients)
VITAMIN D (1158 patients)
ZOCOR (1156 patients)
NORVASC (1115 patients)
ZOFRAN (1100 patients)
SPIRIVA (1095 patients)
SIMVASTATIN (1092 patients)
DECADRON (1091 patients)
TOPROL-XL (1071 patients)
PLAVIX (1070 patients)
MORPHINE (1069 patients)
LEXAPRO (1052 patients)
ATIVAN (1048 patients)
LEVOTHYROXINE SODIUM (1047 patients)
METFORMIN HCL (1042 patients)
PAXIL (1005 patients)
HUMIRA (1000 patients)
GABAPENTIN (984 patients)
CRESTOR (971 patients)
CALCIUM (957 patients)
IBUPROFEN (940 patients)
POTASSIUM CHLORIDE (936 patients)
CLOZARIL (898 patients)
ACCUTANE (879 patients)
LEVAQUIN (862 patients)
ALLOPURINOL (854 patients)
EFFEXOR (848 patients)
VELCADE (848 patients)
MIRALAX (838 patients)
NEXAVAR (828 patients)
METHOTREXATE (816 patients)
CLONAZEPAM (809 patients)
ADVAIR DISKUS 100/50 (805 patients)
LORTAB (787 patients)
COLACE (775 patients)
LACTULOSE (769 patients)
PREDNISOLONE (762 patients)
PROZAC (753 patients)
ALPRAZOLAM (743 patients)
CELEXA (733 patients)
MULTI-VITAMINS (732 patients)
PREMARIN (731 patients)
AVONEX (726 patients)
FENTANYL (721 patients)
DIOVAN (719 patients)
DIGOXIN (719 patients)
LANTUS (708 patients)
MORPHINE SULFATE (707 patients)
ZANTAC (694 patients)
THALIDOMIDE (673 patients)
REGLAN (673 patients)
TYSABRI (668 patients)
WELLBUTRIN (659 patients)
TRAMADOL HCL (656 patients)
TRAZODONE HCL (655 patients)
SANDOSTATIN LAR (645 patients)
KLONOPIN (643 patients)
ZYRTEC (635 patients)
PREDNISONE TAB (632 patients)
DIAZEPAM (631 patients)
EXJADE (627 patients)
CARBOPLATIN (625 patients)
COMPAZINE (623 patients)
HEPARIN SODIUM INJECTION (620 patients)
WARFARIN SODIUM (614 patients)
ALENDRONATE SODIUM (611 patients)
VALIUM (607 patients)
YAZ (592 patients)
GLUCOPHAGE (584 patients)
AMLODIPINE (581 patients)
MULTI-VITAMIN (581 patients)
DILAUDID (581 patients)
FISH OIL (576 patients)
METOPROLOL TARTRATE (575 patients)
FLEXERIL (572 patients)
VESICARE (568 patients)
MS CONTIN (567 patients)
ASCORBIC ACID (566 patients)
ZELNORM (564 patients)
VITAMIN E (561 patients)
INSULIN (558 patients)
RISPERDAL (554 patients)
CLOZAPINE (551 patients)
ACTONEL (551 patients)
CALCIUM CARBONATE (550 patients)
XELODA (542 patients)
ZYPREXA (536 patients)
SINGULAIR (533 patients)
NAMENDA (530 patients)
ZETIA (519 patients)
AVASTIN (510 patients)
CISPLATIN (500 patients)
LANSOPRAZOLE (500 patients)
TYLENOL (498 patients)
FLOMAX (496 patients)
ALLEGRA (495 patients)
SPIRONOLACTONE (493 patients)
FLONASE (487 patients)
METOCLOPRAMIDE (484 patients)
CHEMOTHERAPEUTICS NOS (480 patients)
ACTOS (480 patients)
FOSAMAX PLUS D (479 patients)
THALOMID (479 patients)
RANITIDINE (476 patients)
TAXOTERE (476 patients)
GLIPIZIDE (473 patients)
VITAMIN B-12 (470 patients)
DIANEAL (470 patients)
BACLOFEN (469 patients)
COREG (467 patients)
YASMIN (467 patients)
CLONIDINE (461 patients)
TYLENOL (CAPLET) (457 patients)
AMITRIPTYLINE HCL (456 patients)
VICTOZA (454 patients)
NITROGLYCERIN (453 patients)
BENADRYL (447 patients)
ARANESP (447 patients)
TAXOL (447 patients)
AMOXICILLIN (444 patients)
ULTRAM (442 patients)
CYCLOPHOSPHAMIDE (442 patients)
ENBREL (438 patients)
CIPROFLOXACIN (437 patients)
METOPROLOL (435 patients)
ELAVIL (435 patients)
COZAAR (434 patients)
HYDROCODONE (428 patients)
EFFEXOR XR (428 patients)
CLINDAMYCIN (426 patients)
PROMETHAZINE (426 patients)
CEPHALEXIN (425 patients)
ARIMIDEX (425 patients)
REMICADE (419 patients)
LEVOXYL (416 patients)
ZITHROMAX (415 patients)
RADIATION THERAPY (415 patients)
DULCOLAX (414 patients)
NAPROXEN (414 patients)
SENOKOT (413 patients)
FERROUS SULFATE TAB (412 patients)
PRISTIQ (411 patients)
TAMOXIFEN CITRATE (410 patients)
FLUOROURACIL (408 patients)
TEMAZEPAM (408 patients)
LOVENOX (404 patients)
FEMARA (401 patients)
SUTENT (401 patients)
FLUCONAZOLE (400 patients)
BONIVA (398 patients)
FAMOTIDINE (395 patients)
TOPAMAX (394 patients)
PEPCID (392 patients)
AVANDIA (391 patients)
CLARITIN (389 patients)
NYSTATIN (386 patients)
ENABLEX (382 patients)
VINCRISTINE (381 patients)
REBIF (380 patients)
ACYCLOVIR (380 patients)
GLYBURIDE (374 patients)
ENALAPRIL MALEATE (373 patients)
HYDROCODONE BITARTRATE (370 patients)
IRON (369 patients)
VITAMINS (369 patients)
ONDANSETRON (368 patients)
ACIPHEX (363 patients)
SENNA (359 patients)
METFORMIN (357 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about CONSTIPATION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.